Allianz
EWTX icon

Allianz’s Edgewise Therapeutics EWTX Stock Holding History

Allianz’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$648K Buy
+15,955
New +$678K 0.01% 320

Other funds holding EWTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Allianz's EWTX Position: Q3 2026 in Review

Allianz opened a new position in Edgewise Therapeutics (EWTX) in Q3 2026: 15,955 shares worth $648K. The stake represents 0.01% of the portfolio and ranks #320 among its holdings.

153 funds tracked by Wall St. Rank hold EWTX as of Q3 2026.

  • Allianz held 15,955 shares of Edgewise Therapeutics worth $648K as of Q3 2026.
  • Edgewise Therapeutics was a new Allianz position in Q3 2026.
  • Edgewise Therapeutics made up 0.01% of Allianz's portfolio in Q3 2026, its #320 holding.
  • 153 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2026.

Based on Allianz's 13F filing for Q3 2026, filed 12 Nov 2026.